Approaches to the treatment of visceral pain

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 3, 2007, Pages 171-176

  Bulmer, David C E ^a   Coelho, Anne Marie ^a   Winchester, Wendy J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BMS 562086; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; DDP 225; DESIPRAMINE; DULOXETINE; EVT 101; GABAPENTIN; GW 876008; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN UPTAKE INHIBITOR; OCTREOTIDE; PD 217014; PREGABALIN; RGH 896; SEROTONIN UPTAKE INHIBITOR; SOLABEGRON; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; V 3381;

ANALGESIC ACTIVITY; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; EVIDENCE BASED MEDICINE; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PSYCHOSIS; REVIEW; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN;

EID: 46149101203     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.04.003     Document Type: Review

References (40)

1. Kuiken S.D., et al. Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders - the clinical evidence. Aliment. Pharmacol. Ther. 21 (2005) 633-651
2. Tack J., et al. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment. Pharmacol. Ther. 24 (2006) 183-205
3. Talley N.J. Evaluation of drug treatment in irritable bowel syndrome. Br. J. Clin. Pharmacol. 56 (2003) 362-369
4. Bradesi S., and Mayer E.A. Novel therapeutic approaches in IBS. Curr. Opin. Pharmacol. 7 (2007) 598-604
5. Hillsley K., et al. Direct and indirect actions of 5-hydroxytryptamine on the discharge of mesenteric afferent fibres innervating the rat jejunum. J. Physiol. 506 Pt 2 (1998) 551-561
6. Hicks G.A., et al. Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J. Physiol. 544 (2002) 861-869
7. Mayer E.A., and Bradesi S. Alosetron and irritable bowel syndrome. Expert Opin. Pharmacother. 4 (2003) 2089-2098
8. 3 receptors in a rat model of delayed stress-induced visceral hyperalgesia. Pain 130 (2007) 56-65
9. Schikowski A., et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motil. 14 (2002) 221-227
10. Greenwood-Van Meerveld B., et al. Activation of peripheral 5-HT receptors attenuates colonic sensitivity to intraluminal distension. Neurogastroenterol. Motil. 18 (2006) 76-86
11. Tache Y., and Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J. Clin. Invest. 117 (2007) 33-40
12. Bielefeldt K., et al. Amitriptyline inhibits voltage-sensitive sodium currents in rat gastric sensory neurons. Dig. Dis. Sci. 47 (2002) 959-966
13. Mawe G.M., et al. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment. Pharmacol. Ther. 23 (2006) 1067-1076
14. Aoki M., et al. Antidepressants enhance the antinociceptive effects of carbamazepine in the acetic acid-induced writhing test in mice. Eur. J. Pharmacol. 550 (2006) 78-83
15. Kall E., et al. The serotonin reuptake inhibitor citalopram does not affect colonic sensitivity or compliance in rats. Eur. J. Pharmacol. 570 (2007) 203-211
16. Mease P.J., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J. Rheumatol. (2008)
17. Lee K.J., et al. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 22 (2005) 981-988
18. Houghton L.A., et al. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 56 (2007) 1218-1225
19. Cheng J.K., and Chiou L.C. Mechanisms of the antinociceptive action of gabapentin. J. Pharmacol. Sci. 100 (2006) 471-486
20. 2+ channel alpha2delta ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 28 (2007) 75-82
21. Davies A., et al. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. Trends Pharmacol. Sci. 28 (2007) 220-228
22. Field M.J., et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 17537-17542
23. Diop L., et al. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J. Pharmacol. Exp. Ther. 302 (2002) 1013-1022
24. Eutamene H., et al. Antinociceptive effect of pregabalin in septic shock-induced rectal hypersensitivity in rats. J. Pharmacol. Exp. Ther. 295 (2000) 162-167
25. Ohashi K., et al. Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats. Pharmacology 81 (2008) 144-150
26. Nozu T., and Kudaira M. Corticotropin-releasing factor induces rectal hypersensitivity after repetitive painful rectal distention in healthy humans. J. Gastroenterol. 41 (2006) 740-744
27. Sagami Y., et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53 (2004) 958-964
28. Martinez V., and Tache Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr. Pharm. Des. 12 (2006) 4071-4088
29. Booth C.E., et al. Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology 121 (2001) 358-369
30. Su X., et al. Effects of octreotide on responses to colorectal distension in the rat. Gut 48 (2001) 676-682
31. Cellek S., et al. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology 133 (2007) 175-183
32. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5 (2006) 160-170
33. Willert R.P., et al. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-d-aspartate receptor. Gastroenterology 126 (2004) 683-692
34. Dickenson A.H. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol. Sci. 11 (1990) 307-309
35. Lipton S.A. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr. Drug Targets 8 (2007) 621-632
36. Coutinho S.V., et al. The role of CNS NMDA receptors and nitric oxide in visceral hyperalgesia. Eur. J. Pharmacol. 429 (2001) 319-325
37. McRoberts J.A., et al. Role of peripheral N-methyl-d-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 120 (2001) 1737-1748
38. Traub R.J., et al. NMDA receptor antagonists attenuate noxious and nonnoxious colorectal distention-induced Fos expression in the spinal cord and the visceromotor reflex. Neuroscience 113 (2002) 205-211
39. Barbara G., et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132 (2007) 26-37
40. Cenac N., et al. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest. 117 (2007) 636-647